Understand the Type 2 Diabetes Pipeline and the Factors That Indicate That It Is Becoming More Innovative

Type 2 diabetes is a major public health concerns in both the developed as well as the developing countries in the Asia Pacific. According to the International Diabetes Federation, nearly 387 million people around the world have diabetes and majority of these cases will be Type 2 diabetes.


Albany, NY -- (SBWIRE) -- 07/05/2016 -- The leading business intelligence provider, has released its latest research, "Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 Increasing Uptake of Novel Drug Classes to Drive Market Growth", which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts.

Read Complete Report @ http://www.mrrse.com/type-2-diabetes-therapeutics-in-asia-pacific-markets

In 2013, the value of the type 2 diabetes therapeutics market in APAC countries was an estimated $6.5 billion, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% between 2013 and 2020 to $10.5 billion. This strong growth is due to the anticipated approval of products in relatively novel treatment classes, such as Glucagon-Like Peptide-1 (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, and Sodium Glucose Transporter-2 (SGLT-2) inhibitors, as well as the growth of the prevalence population in the APAC region, particularly in India and China.


The report analyzes the treatment use patterns, market characterization, pipeline analysis and key licensing and co-development deals of the type 2 diabetes in the APAC markets of China, India, Japan, and Australia.It includes

A brief introduction to type 2 diabetes, including its pathophysiology, etiology, diagnosis and treatment algorithms

In-depth analysis of currently marketed drugs for type 2 diabetes, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy

A comprehensive review of the pipeline for type 2 diabetes, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed by Phase distribution, molecule type, program type, mechanism of action and molecular target

Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type

Multi-scenario market forecast data to 2020, taking into account how the market might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the key developed markets

Discussion of the drivers of and barriers to market growth

In-depth analysis of all licensing and co-development deals that have occurred in the type 2 diabetes market since 2006

Get a Free Sample Copy of the Report @ http://www.mrrse.com/sample/130

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.